Remission with mirtazapine and selective serotonin reuptake inhibitors: A meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression

International Clinical Psychopharmacology

Volumn 25, Issue 4, 2010, Pages 189-198

  Thase, Michael E ^a   Nierenberg, Andrew A ^b   Vrijland, Peter ^c   Van Oers, Helga J J ^c   Schutte, Albert Jan ^d   Simmons, John H ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Organon International Inc   (Netherlands)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Controlled trial; Meta analysis; Mirtazapine; Remission; Selective serotonin reuptake inhibitors

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; PAROXETINE; PLACEBO; SERTRALINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; FLUVOXAMINE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PAROXETINE; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953693729     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328330adb2     Document Type: Article

References (39)

1. Behnke K, Sogaard J, Martin S, Bauml J, Ravindran AV, Agren H, Vester-Blokland ED (2003). Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol 23:358-364.
2. Benkert O, Szegedi A, Kohnen R (2000). Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 61:656-663.
3. Benkert O, Szegedi A, Philipp M, Kohnen R, Heinrich C, Heukels A, et al. (2006). Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol 26:75-78
4. Blier P (2003). The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 13:57-66.
5. Cipriani A, Barbui C, Brambilla P, Furukawa TA, Hotopf M, Geddes JR (2006). Are all antidepressants really the same? The case of fluoxetine: a systematic review. J Clin Psychiatry 67:850-864.
6. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746-758.
7. DSM-III-R (1987). Diagnostic and statistical manual of mental disorders. 3 revised ed. Washington, DC: American Psychiatric Association.
8. DSM-IV(1994). Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association.
9. Edwards JG, Anderson I (1999). Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57:507-533.
10. Freemantle N, Anderson IM, Young P (2000). Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. Br J Psychiatry 177:292-302.
11. Guelfi JD, Ansseau M, Timmerman L, Korsgaard S (2001). Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 21:425-431.
12. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
13. Hong CJ, Hu WH, Chen CC, Hsiao CC, Tsai SJ, Ruwe FJ (2003). A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry 64:921-926.
14. Keller MB (2003). Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 289: 3152-3160.
15. Kennedy SH, Andersen HF, Lam RW (2006). Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 31:122-131.
16. Koch GG, Edwards S (1988). Clinical efficacy in trials with categorical data. In: Peace KK, editor. Biopharmaceutical statistics for drug development. New York: Marcel Dekker; pp. 403-457.
17. Leinonen E, Skarstein J, Behnke K, Agren H, Helsdingen JT (1999). Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 14:329-337.
18. Lieberman JA, Greenhouse J, Hamer RM, Krishnan KR, Nemeroff CB, Sheehan DV, et al. (2005). Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsycho-pharmacology 30:445-460.
19. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
20. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME (2008). Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 63:424-434.
21. Owens MJ, Knight DL, Nemeroff CB (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50:345-350.
22. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 62:1217-1227.
23. Quitkin FM, Taylor BP, Kremer C (2001). Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry 62:358-361.
24. Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM Jr (2002). Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 10:541-550.
25. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002). Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180: 396-404.
26. Thase ME (2002). Comparing the methods used to compare antidepressants. Psychopharmacol Bull 36 (Suppl 1):1-17.
27. Thase ME (2003). Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry 64 (Suppl 13):18-25.
28. Thase ME, Entsuah AR, Rudolph RL (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241.
29. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ (2007). Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 27:672-676.
30. Thase ME (2004). Mirtazapine versus sertraline in SSRI treatment resistant depression. J Affect Disord 78 (Suppl 1):S49.
31. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358:252-260.
32. Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ (2005). Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 19:137-146.
33. Wade A, Crawford GM, Angus M, Wilson R, Hamilton L (2003). A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol 18:133-141.
34. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, et al. (2008). Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. J Clin Psychiatry 69:1404-1415.
35. Weinmann S, Becker T, Koesters M (2008). Re-evaluation of the efficacy and tolerability of venlafaxine vs. SSRI: meta-analysis. Psychopharmacology (Berl) 196:511-520.
36. Westenberg HG (1999). Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry 60 (Suppl 17):4-8.
37. Wheatley DP, van Moffaert M, Timmerman L, Kremer CM (1998). Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry 59:306-312.
38. World Health Organization (2003). ATT/DDD Classification. Oslo: Norwegian Institute of Public Health.
39. Zimmerman M, Posternak MA, Chelminski I (2004). Defining remission on the Montgomery-Asberg depression rating scale. J Clin Psychiatry 65: 163-168.